Abstract:ABSTRACT Human metapneumovirus (HMPV) is a primary cause of acute respiratory infection, yet there are no approved vaccines or antiviral therapies for HMPV. Early host responses to HMPV are poorly characterized, and further understanding could identify important antiviral pathways. Type III interferon (IFN-λ) displays potent antiviral activity against respiratory viruses and is being investigated for therapeutic use. However, its role in HMPV infection remains largely unknown. Here, we show that IFN-λ is highly upregulated during HMPV infection in vitro in human and mouse airway epithelial cells and in vivo in mice. We found through several immunological and molecular assays that type II alveolar cells are the primary producers of IFN-λ. Using mouse models, we show that IFN-λ limits lung HMPV replication and restricts virus spread from upper to lower airways but does not contribute to clinical disease. Moreover, we show that IFN-λ signaling is predominantly mediated by CD45 - non-immune cells. Mice lacking IFN-λ signaling showed diminished loss of ciliated epithelial cells and decreased recruitment of lung macrophages in early HMPV infection along with higher inflammatory cytokine and interferon-stimulated gene expression, suggesting that IFN-λ may maintain immunomodulatory responses. Administration of IFN-λ for prophylaxis or post-infection treatment in mice reduced viral load without inflammation-driven weight loss or clinical disease. These data offer clinical promise for IFN-λ in HMPV treatment. IMPORTANCE Human metapneumovirus (HMPV) is a common respiratory pathogen and often contributes to severe disease, particularly in children, immunocompromised people, and the elderly. There are currently no licensed HMPV antiviral treatments or vaccines. Here, we report novel roles of host factor IFN-λ in HMPV disease that highlight therapeutic potential. We show that IFN-λ promotes lung antiviral responses by restricting lung HMPV replication and spread from upper to lower airways but does so without inducing lung immunopathology. Our data uncover recruitment of lung macrophages, regulation of ciliated epithelial cells, and modulation of inflammatory cytokines and interferon-stimulated genes as likely contributors. Moreover, we found these roles to be distinct and non-redundant, as they are not observed with knockout of, or treatment with, type I IFN. These data elucidate unique antiviral functions of IFN-λ and suggest IFN-λ augmentation as a promising therapeutic for treating HMPV disease and promoting effective vaccine responses.

IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN

Interferon-λ enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin

Interferon-λ modulates dendritic cells to facilitate T cell immunity during infection with influenza A virus

Differential Interferon-Α Subtype Induced Immune Signatures Are Associated with Suppression of SARS-CoV-2 Infection.

Targeting IFN-λ Signaling Promotes Recovery from Central Nervous System Autoimmunity

IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes

Differential interferon-α subtype immune signatures suppress SARS-CoV-2 infection

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Interferon-mediated NK cell activation is associated with limited neutralization breadth during SARS-CoV-2 infection

IFN-γ derived from activated human CD4+ T cells inhibits the replication of SARS-CoV-2 depending on cell-type and viral strain

A Commentary of “type I Interferon Deficiency Can Lead to Severe COVID-19” in 10 Remarkable Discoveries from 2020 in Nature

Type-II IFN inhibits SARS-CoV-2 replication in human lung epithelial cells and ex vivo human lung tissues through indoleamine 2,3-dioxygenase-mediated pathways

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome

Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity

Transgenic mouse models support a protective role of type I IFN response in SARS-CoV-2 infection-related lung immunopathology and neuroinvasion

IFN-λ drives distinct lung immune landscape changes and antiviral responses in human metapneumovirus infection

An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity.

Murine Type III interferons are functionally redundant and correlate with bacterial burden during influenza/bacterial super-infection

Type III interferon exerts thymic stromal lymphopoietin in mediating adaptive antiviral immune response

Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus

Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections